Percutaneous Lymph Node Recurrence Ablation

Background and indications

Percutaneous lymph node recurrence ablation (cryoablation, RFA, or MWA) is offered for localized tumor recurrences in lymph nodes when surgery is complex (reoperation in previously operated site) or the patient is not a surgical candidate. Common locations include pelvic (cervical cancer, rectal), retroperitoneal, mediastinal, and cervical recurrences.

Pre-procedure assessment

Assessment includes PET-CT (confirming metabolic activity and excluding other recurrence sites), zone CT or MRI, percutaneous biopsy (if histological diagnosis needed), and tumor board discussion.

Procedure

Under general anesthesia and CT guidance, one or more ablation needles are positioned in the tumor-bearing node. Cryoablation is preferred near neural structures (sacral plexus, sciatic nerve). Hydrodissection may protect adjacent structures. The procedure takes 1 to 2 hours.

Results and scientific evidence

Published series report 70-85% local control rate at 12 months for pelvic and retroperitoneal lymph node recurrences. Pain improvement is achieved in 80-90% of symptomatic cases. This approach may delay or avoid systemic treatments in oligometastatic recurrences.

Risks and complications

Local pain (20-40%), transient neuropathy (5-10%, if nerve proximity), hematoma (< 5%), infection (< 2%). Risk of adjacent structure injury (ureter, vessels) is minimized by imaging guidance and hydrodissection.

Recovery

1-2 night hospitalization. Control PET-CT at 3 and 6 months.

Practical information

The procedure is performed as a short inpatient stay. It is performed by an interventional oncology radiologist.